evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

17 questions · 19 findings · 5 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 5 · 26.3%GRADE not reported 0 · 0%Very low 7 · 36.8%Low 5 · 26.3%Moderate 2 · 10.5%High 0 · 0%

Infliximab 5 mg/kg vs infliximab 10 mg/kg

Withdrawals due to adverse events · Patients with active Crohn's disease

The review found no eligible studies for this question.

2 findings from 1 review

Infliximab vs placebo

Withdrawals due to adverse events · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)

It is very uncertain whether infliximab changes withdrawal due to adverse events (at 32‐54 weeks) compared with placebo (very low certainty).

1 finding from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Withdrawals due to adverse outcomes · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).

1 finding from 1 review

Infliximab 5–10 mg/kg vs placebo

Withdrawals due to adverse events · Patients with active Crohn's disease

The review found no eligible studies for this question.

2 findings from 1 review

Infliximab combined with purine analogues vs purine analogues

Withdrawals due to adverse events · Participants with Crohn's disease in remission

It is very uncertain whether infliximab combined with purine analogues changes withdrawal due to adverse events (at 48 weeks) compared with purine analogues (very low certainty).

1 finding from 1 review

Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues

Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)

It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes withdrawal due to adverse events (at 30 weeks) compared with intravenous CT‐P13 and purine analogues (very low certainty).

1 finding from 1 review